COYA
Coya Therapeutics Inc

1,017
Loading...
Loading...
News
all
press releases
Coya Therapeutics, Inc. (COYA) Now Trades Above Golden Cross: Time to Buy?
Is it a good or bad thing when a stock experiences a golden cross technical event?
Zacks·17d ago
News Placeholder
More News
News Placeholder
Coya Therapeutics, Inc. (COYA) Reports Q2 Loss, Lags Revenue Estimates
Coya Therapeutics, Inc. (COYA) delivered earnings and revenue surprises of -63.64% and -96.10%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates
Regenxbio (RGNX) delivered earnings and revenue surprises of -22.12% and -21.16%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -26.87% and -32.29%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Coya Therapeutics, Inc. (COYA) Surges 10.7%: Is This an Indication of Further Gains?
Coya Therapeutics, Inc. (COYA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·2mo ago
News Placeholder
Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimers Disease Using GLP-1 Agonists and Combinations
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief...
Business Wire·7mo ago
News Placeholder
Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimers Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announced encouraging...
Business Wire·7mo ago
News Placeholder
Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief...
Business Wire·7mo ago
News Placeholder
Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces the...
Business Wire·8mo ago
News Placeholder
Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that five of...
Business Wire·9mo ago

Latest COYA News

View

Advertisement. Remove ads.

Advertisement. Remove ads.